Migraine-specific preventive therapies should be in the primary care toolbox, according to headache specialist Jessica Ailani, MD.
"These newer [migraine] therapies are geared for primary care. Their side effect profile is fantastic...they're easy to use...and primary care providers are very comfortable with monoclonal antibodies," said migraine specialist and researcher Jessica Ailani, MD, while speaking with Patient Care.
In the rest of our conversation, captured below, Ailani discussed the remarkable results some migraine patients are experiencing with the calcitonin gene-related peptide inhibitors and other new targeted drug classes as well as the opportunities for effective primary care-specialist cotreatment.